tldrdailynews.com logo

Scribe Therapeutics files for Nasdaq IPO to test appetite for early-stage biotech

1 min read
Source: Endpoints News
Scribe Therapeutics files for Nasdaq IPO to test appetite for early-stage biotech
Photo: Endpoints News
TL;DR Summary

Scribe Therapeutics filed for a Nasdaq IPO to gauge investor appetite for early-stage biotech and gene-editing startups, backed by major investors including RA Capital, Andreessen Horowitz, OrbiMed and Avoro Capital.

Topics:business#biotech#biotech-funding#biotech-ipo#early-stage-biotech#gene-editing#scribe-therapeutics
Share this article
  1. Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs  Endpoints News
  2. Scribe Therapeutics Stockholders Include Eli Lilly  Moomoo
  3. Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com  Investing.com South Africa
  4. Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches  The Business Journals
  5. SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO  renaissancecapital.com

Reading Insights

Total Reads

0

Unique Readers

3

Time Saved

3 min

vs 4 min read

Condensed

95%

613 → 30 words

Want the full story? Read the original article

Read on Endpoints News